Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ArgiNOx Phamaceuticals.

Request full access

Biopharmaceutical company engaged in the discovery and development of drugs for cardiovascular pathologies

Redwood City, United StatesFounded 2000Biotech & Life Sciences

About ArgiNOx Phamaceuticals.

ArgiNOx Pharmaceuticals, Inc. operated as a specialty pharmaceutical firm concentrating on the discovery and development of drugs for cardiovascular diseases, with a specific focus on treatments for hospitalized patients. Originally incorporated as Juventis, Inc. in 2000, the company was re-established as ArgiNOx Pharmaceuticals in 2002 and was headquartered in Menlo Park, California. The company's scientific foundation was built upon Nobel prize-winning research into the role of nitric oxide (NO) in various physiological functions.

The company's primary business was centered on research and development to manufacture drugs for cardiovascular pathologies. ArgiNOx's lead drug candidate was Tilarginine Acetate Injection, a synthetically produced small molecule designed to inhibit the production of nitric oxide. This therapeutic was developed to treat cardiogenic shock, a life-threatening condition that can occur after a severe heart attack, affecting a significant number of patients who reach the hospital. The business model was typical of a clinical-stage biopharmaceutical company, involving significant investment in research, clinical trials, and regulatory processes, with the ultimate goal of commercializing its proprietary drug candidates.

A significant milestone for ArgiNOx was securing a total of $42 million in funding. This included a Series C funding round on March 1, 2005, where the company raised $25 million from investors including Topspinventure.com and Perseus Soros Biopharmaceutical Fund. Following this, in June 2005, ArgiNOx initiated a pivotal Phase III clinical trial, known as TRIUMPH, for its lead compound, tilarginine. The former president and CEO was Kenneth Drazan. Despite its progress, the company ultimately ceased operations and is now considered defunct.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2000
Headquarters
Redwood City, United States
Employees
2
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Mar 2005 $25M $100M Undisclosed —
SERIES B✓Equity / VC Jun 2004 $8M $32M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ArgiNOx Phamaceuticals. website traffic

Latest recorded traffic for ArgiNOx Phamaceuticals. is 0 monthly website visits. ArgiNOx Phamaceuticals.'s team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Rivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health Charlottesville, United States Operational 33 $167M $528M
Vero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions Atlanta, United States Operational
ImaginepharmaDeveloping therapies using its IMG-1 polypeptide for oral delivery, regenerative medicine, and novel therapeutics Pittsburgh, United States Low Activity
Banook GroupComprehensive clinical trial solutions with a focus on cardiac safety, endpoint adjudication, and central imaging Nancy, France Acquired
BiofourmisBiotechnology company that augments personalized care and therapies using digital therapeutics Boston, United States Operational
Gene Techno ScienceGene Techno Science is engaged in the research and development of biopharmaceutical products and biosimilars in Japan Sapporo, Japan Acquired
AdrenomedAn innovative biomarker-guided precision medicine solution for patients in acute care with sepsis and septic shock Hennigsdorf, Germany Operational
Critical PressureVirtual biopharmaceutical company developing products to treat vascular dysfunction and shock Cambridge, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ArgiNOx Phamaceuticals. in the Redwood City ecosystem

Live from Dealroom

The ArgiNOx Phamaceuticals. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Redwood City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ArgiNOx Phamaceuticals. on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ArgiNOx Phamaceuticals.’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.